MBCproject_0280_T1_RNA
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEME_METABOLISM+0.670
- E2F_TARGETS+0.540
- G2M_CHECKPOINT+0.490
- ALLOGRAFT_REJECTION+0.360
- SPERMATOGENESIS+0.300
- IL6_JAK_STAT3_SIGNALING+0.160
- INFLAMMATORY_RESPONSE+0.130
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.110
- KRAS_SIGNALING_DN+0.090
- PANCREAS_BETA_CELLS+0.020
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.620
- ANGIOGENESIS-0.480
- CHOLESTEROL_HOMEOSTASIS-0.460
- ESTROGEN_RESPONSE_EARLY-0.460
- UV_RESPONSE_DN-0.450
- TGF_BETA_SIGNALING-0.430
- MYOGENESIS-0.410
- NOTCH_SIGNALING-0.400
- WNT_BETA_CATENIN_SIGNALING-0.390
- APICAL_JUNCTION-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CR-5248-01A-01R-2016-07 | — | — | 0.826 |
| 2 | PL21_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.810 |
| 3 | SRR25617823 | — | D | 0.793 |
| 4 | SRR2932833 | — | — | 0.783 |
| 5 | ERR2208907 | — | — | 0.779 |
| 6 | SRR25617831 | — | D | 0.779 |
| 7 | TCGA-CR-7404-01A-11R-2132-07 | — | — | 0.773 |
| 8 | OCIAML2_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.768 |
| 9 | TCGA-DQ-7591-01A-11R-2081-07 | — | — | 0.767 |
| 10 | TCGA-85-A4PA-01A-11R-A24Z-07 | — | cohortMD2 | 0.756 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEME_METABOLISM | 0.670 | Temsirolimus | — uncovered |
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.490 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.360 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.160 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.130 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.020 | Cobimetinib | — uncovered |
| COMPLEMENT | 0.010 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.010 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.010 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.010 | Inavolisib | — uncovered |